SLN (Silence Therapeutics) Cyclically Adjusted Book per Share: $2.13 (As of Mar. 2026)


SLN Silence Therapeutics PLC SLN
45 GF Score
Price $10.07
GF Value $0.23
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Silence Therapeutics Cyclically Adjusted Book per Share?

Silence Therapeutics SLN +1.40% 45 Cyclically Adjusted Book per Share is $2.13 as of Mar. 2026. GuruFocus rates SLN with a GF Score™ of 45/100 and a GF Value™ of $0.23 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Silence Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $1.046. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.13 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Silence Therapeutics's average Cyclically Adjusted Book Growth Rate was -58.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -45.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -36.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Silence Therapeutics was -20.30% per year. The lowest was -45.10% per year. And the median was -30.50% per year.

As of today (2026-06-28), Silence Therapeutics's current stock price is $10.065. Silence Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $2.13. Silence Therapeutics's Cyclically Adjusted PB Ratio of today is 4.73.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Silence Therapeutics was 5.44. The lowest was 0.13. And the median was 0.82.


Silence Therapeutics  (NAS:SLN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Silence Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=10.065/2.13
=4.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Silence Therapeutics was 5.44. The lowest was 0.13. And the median was 0.82.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Silence Therapeutics Cyclically Adjusted Book per Share Related Terms


Silence Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Silence Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silence Therapeutics Cyclically Adjusted Book per Share Chart

Silence Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.79 28.62 42.73 5.71 3.07

Silence Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.89 5.91 4.62 3.07 2.13

SLN vs CRBP, TTRX, AGEN: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Silence Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Cyclically Adjusted PB Ratio falls into.


SLN
45GF Score
Silence Therapeutics PLC SLN
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Silence Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Silence Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.046/140.8000*140.8000
=1.046

Current CPI (Mar. 2026) = 140.8000.

Silence Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201206 3.293 95.600 4.850
201212 3.968 97.300 5.742
201306 3.631 98.000 5.217
201312 3.105 99.200 4.407
201406 3.471 99.800 4.897
201412 2.570 99.900 3.622
201506 5.035 100.100 7.082
201512 4.195 100.400 5.883
201606 3.297 101.000 4.596
201612 2.873 102.200 3.958
201706 2.711 103.500 3.688
201712 3.034 105.000 4.068
201806 2.462 105.900 3.273
201812 1.898 107.100 2.495
201906 1.450 107.900 1.892
201912 1.095 108.500 1.421
202006 1.265 108.800 1.637
202009 0.000 109.200 0.000
202012 0.445 109.400 0.573
202103 0.000 109.700 0.000
202106 1.095 111.400 1.384
202109 0.734 112.400 0.919
202112 0.384 114.700 0.471
202203 0.175 116.500 0.212
202206 -0.192 120.500 -0.224
202209 1.062 122.300 1.223
202212 0.743 125.300 0.835
202303 0.570 126.800 0.633
202306 0.421 129.400 0.458
202309 0.631 130.100 0.683
202312 0.555 130.500 0.599
202403 3.359 131.600 3.594
202406 3.041 133.000 3.219
202409 2.679 133.500 2.825
202412 2.838 135.100 2.958
202503 -2.387 136.100 -2.469
202506 1.993 138.400 2.028
202509 1.568 138.900 1.589
202512 1.319 139.900 1.327
202603 1.046 140.800 1.046

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $2.13 mean?
Silence Therapeutics (SLN) has a Cyclically Adjusted Book per Share of $2.13 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Silence Therapeutics and its competitors.
Is Silence Therapeutics' Cyclically Adjusted Book per Share too high?
Silence Therapeutics' current Cyclically Adjusted Book per Share is $2.13. Overall, Silence Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Cyclically Adjusted Book per Share compare to CRBP and TTRX?
Silence Therapeutics' Cyclically Adjusted Book per Share of $2.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Silence Therapeutics and its competitors. Silence Therapeutics's current Cyclically Adjusted Book per Share is $2.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.23, compared to a current price of $10.07 — trading 4276.1% above its estimated fair value. The current Cyclically Adjusted Book per Share is $2.13. Silence Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current Cyclically Adjusted Book per Share is $2.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Silence Therapeutics (SLN) Overvalued in 2026?

Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued. The current stock price of $10.07 is trading 4276.1% above its estimated GF Value™ of $0.23. GuruFocus considers Silence Therapeutics to be Significantly Overvalued.

Key valuation signals for SLN:

  • Cyclically Adjusted Book per Share: $2.13
  • GF Value™: $0.23 vs. price of $10.07 (4276.1% above fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Silence Therapeutics Business Description

Other Exchanges SLNCF:USAXRP2:Germany
Address 12 Hammersmith Grove, London, GBR, W6 7AP
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
45GF Score

Get the complete analysis for SLN

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.07
Price
$0.23
GF Value